Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 7/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | FYN | P06241 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944439 | 0.93 | TTK (0.45) | KDM4EALDH1A1F2RL3FYN | |
| SCHEMBL1945044 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1F2RL3FYNMAPT | |
| SCHEMBL1944146 | 0.83 | RAB9A (0.49) | KDM4EALDH1A1F2RL3FYNMAPT | |
| SCHEMBL1946532 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1F2RL3FYNMAPT | |
| SCHEMBL1945276 | 0.82 | MAPT (0.45) | KDM4EFYNMAPTMKNK1LMNA | |
| SCHEMBL1944318 | 0.82 | MKNK1 (0.45) | KDM4EF2RL3FYNMAPTMKNK1 | |
| SCHEMBL1944253 | 0.81 | TP53 (0.53) | KDM4EF2RL3FYNMAPTMKNK1 | |
| SCHEMBL1944353 | 0.80 | MAPT (0.47) | KDM4EALDH1A1F2RL3MAPTLMNA | |
| SCHEMBL2258605 | 0.80 | FYN (0.51) | IKBKBFYN | |
| SCHEMBL1944812 | 0.80 | THRB (0.48) | KDM4EALDH1A1F2RL3FYNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2193133-B1 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-19 | — | — | EP | disclosed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8563550-B2 | Imidazolothiadiazoles for use as protein kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) | 2013-10-22 | — | — | US | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-08-04 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | KDM4E 1465/4885ALDH1A1 2966/4885IKBKB 298/4885 |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | KDM4E 2685/4885ALDH1A1 416/4885IKBKB 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.